<DOC>
	<DOCNO>NCT01959841</DOCNO>
	<brief_summary>To evaluate efficacy safety ASP2151 ( 200 mg 400 mg ) comparison valaciclovir ( VACV ) 3000 mg patient herpes zoster .</brief_summary>
	<brief_title>Phase III Study ASP2151 Herpes Zoster Patients</brief_title>
	<detailed_description>A double-blind , randomize , parallel-group study conduct evaluate efficacy safety ASP2151 ( 200 mg 400 mg ) comparison valaciclovir ( VACV ) 3000 mg patient herpes zoster . The efficacy evaluate primary endpoint define , `` proportion subject achieve cessation new lesion formation Day 4 study treatment '' demonstrate non-inferiority ASP2151 VACV . The safety evaluate base adverse event , laboratory test , vital sign , ECGs .</detailed_description>
	<mesh_term>Herpes Zoster</mesh_term>
	<mesh_term>Valacyclovir</mesh_term>
	<mesh_term>Acyclovir</mesh_term>
	<criteria>( 1 ) Patients rash associate herpes zoster , start receive study drug within 72 hour onset rash 1 . Patients expect adequate response oral antiviral medication 2 . An extreme decline immune function 3 . Presence serious complication 4 . Patients find meet follow condition base laboratory test perform within 14 day inform consent : AST ALT ≥ 2.5 x upper limit normal Platelet count &lt; low limit normal Serum creatinine ≥ 1.5 mg/dL Creatinine clearance &lt; 50 mL/min 5 . Current previous history malignant tumor within 5 year inform consent 6 . Diagnosis autoimmune disease 7 . Evidence bone marrow suppression</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>79 Years</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>